Deutsche Bank Aktiengesellschaft Upgrades Sanofi (NASDAQ:SNY) to “Hold”

Sanofi (NASDAQ:SNY) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report issued on Thursday,Briefing.com Automated Import reports.

Separately, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Sanofi Trading Up 3.8 %

Shares of NASDAQ:SNY traded up $1.99 during mid-day trading on Thursday, hitting $54.14. The company had a trading volume of 4,532,973 shares, compared to its average volume of 2,650,813. The company has a market capitalization of $137.41 billion, a PE ratio of 27.62, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57. Sanofi has a one year low of $45.22 and a one year high of $58.97. The firm has a fifty day moving average price of $48.99 and a 200 day moving average price of $52.22. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. As a group, research analysts forecast that Sanofi will post 3.82 EPS for the current year.

Hedge Funds Weigh In On Sanofi

A number of hedge funds have recently bought and sold shares of SNY. Synergy Asset Management LLC purchased a new stake in shares of Sanofi during the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. increased its position in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of Sanofi during the 3rd quarter worth $29,000. Concord Wealth Partners boosted its holdings in shares of Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares during the last quarter. Finally, Fortitude Family Office LLC increased its holdings in Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.